Plus Therapeutics has entered into an agreement with SpectronRx to support late‑stage clinical manufacturing of its radiopharmaceutical candidate Reyobiq (rhenium Re-186 obisbemeda) and the rhenium‑186 isotope.
Under an existing master services agreement (MSA), SpectronRx will become a second GMP manufacturing partner alongside Radiomedix, Plus Therapeutics said in its announcement. Rhenium‑186 isotope supply will continue to be provided through Telix Pharmaceuticals, Plus noted.
The agreement provides for a technology transfer of the Reyobiq manufacturing process, rhenium‑186 isotope processing, analytical methods, and technical and regulatory expertise to support future commercial‑scale production, the company said. SpectronRx’s Indiana facility will offer on‑demand production of both the rhenium‑186 isotope and the finished Reyobiq drug product within the same site, according to the firm.
The partnership supports the goal of completing manufacturing scale‑up for Reyobiq late‑stage clinical supply by 2026. The radiopharmaceuticals target central nervous system (CNS) cancers.
Reyobiq is being evaluated for the treatment of recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer in the ReSPECT-GBM, ReSPECT-LM, and ReSPECT-PBC clinical trials, Plus Therapeutics noted.
